
Celerion is the premier provider of innovative early stage clinical research solutions.
Formed through the acquisition of the early stage development operations of MDS Pharma Services, Celerion has a full spectrum of resources to meet the needs of the pharmaceutical, biotechnology and generic industries for Phase 0 through IIa proof-of-concept studies. From facilities strategically located around the world, advanced scientific and technological expertise is applied to:
- Clinical research: phase 0, I and IIa, NDA-enabling clinical pharmacology, and ADME
- Clinical pharmacology sciences: modeling and simulation, study design and protocol development, sata management, biostatistics, and PK/PD and medical writing and reporting
- Bioanalytical services, including discovery through late stage
- Drug development services
Celerion's focus is on the implementation of innovative strategies to generate key data very early to enable go/no-go decisions on drug development. With a clinical capacity of more than 730 beds (24 in-hospital), efficient bioanalytical laboratories and experienced scientific staff, Celerion offers one of the most experienced clinical pharmacology research networks in the industry.
Celerion's combination of experienced people, scientific excellence and state-of-the-art facilities strongly positions the company as the industry leader in the conduct of early clinical research and bioanalytical studies.

Contact details:
Celerion
621 Rose St.
Lincoln, NE 68502
+1.402.476.2811
info@celerion.com
www.celerion.com
Fields marked * are compulsory